PND22 QUANTIFYING COST OUTCOMES DIFFERENTIATED BY GENDER AND AGE IN THE TREATMENT OF MIGRAINE HEADACHE USING STEP AND STRATIFIED CARE by Furiak, N, Bansal, M

Get full text

Use of a decision tree model to estimate the economic benefits of reducing schizophrenia illness relapse by Furiak, N, Klein, R.W, Gahn, J.C, Camper, S.B, Summers, K

Get full text

PDB18 Validation of a Diabetes Modeling Framework by Furiak, N, Bansal, M, Gahn, J.C, Klein, R.W, Smolen, H.J

Get full text

PND6 MODELING THE ESTIMATED COST-SAVINGS OF STRATIFIED CARE FOR MIGRAINE HEADACHES FROM A U.S. PERSPECTIVE by Furiak, N, Bansal, M

Get full text

PMH43 - Use of a decision tree model to estimate the economic benefits of reducing schizophrenia illness relapse by Furiak, N., Klein, R.W., Gahn, J.C., Camper, S.B., Summers, K.

Get full text

PDB74 BETA-VERIFICATION OF A DIABETES MODELING FRAMEWORK AGAINST PUBLISHED COHORT TRIALS by Furiak, N., Bansal, M., Gahn, J.C., Smolen, H.

Get full text

PDB33 EVALUATION OF COST AND CLINICAL OUTCOMES BY HBA1C AT DIAGNOSIS USING VARIOUS DIABETES TREATMENT STRATEGIES by Lee, LJ, Klein, RW, Klein, TM, Furiak, N, Peltz, G, Bansal, M, Jackson, JA, Juneja, R

Get full text

PDB74 BETA-VERIFICATION OF A DIABETES MODELING FRAMEWORK AGAINST PUBLISHED COHORT TRIALS by Furiak, N, Bansal, M, Gahn, J.C, Smolen, H

Get full text

PMC30 USING AN ENCOUNTER-BASED DATABASE TO VALIDATE A DISEASE PROGRESSION MODEL: LESSONS FOR MODELERS by Klein, TM, Wielage, RC, Furiak, NM, Klein, RW

Get full text

PMH21 COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES by Ascher-Svanum, H, Furiak, NM, Klein, RW, Montgomery, W, Smolen, LJ, Lawson, AH, Conley, RR

Get full text

PMH35 COST-EFFECTIVENESS OF ORALLY DISSOLVING OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA IN THE USA by Ascher-Svanum, H, Furiak, NM, Klein, RW, Smolen, LJ, Watson, PR, Lawson, AH

Get full text

PMH38 ADHERENCE LEVELS AND DIFFERENTIAL USE OF MENTAL HEALTH SERVICES IN THE TREATMENT OF SCHIZOPHRENIA by Thomas, NA, Zhu, B, Ascher-Svanum, H, Faries, D, Montgomery, W, Furiak, NM

Get full text

PMH23 COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US by Ascher-Svanum, H, Furiak, NM, Klein, RW, Smolen, LJ, Zhu, B

Get full text